article thumbnail

Public Health Product Hops

Bill of Health

Yet Dmitry Karshtedt held otherwise at the ASLME Health Law Professor’s Conference in Atlanta, GA in 2017. In each scenario, public health considerations drove the product switches and the FDA actively encouraged the development of reformulated products. My talk was titled “Legal Approaches to Ensuring Timely Generic Drug Availability.”

article thumbnail

FDA, MITRE Update Medical Device Cybersecurity Regional Incident Preparedness and Response Playbook

HIPAA Journal

Following the WannaCry ransomware attacks in 2017, which caused massive disruption to clinical operations at several U.S. The post FDA, MITRE Update Medical Device Cybersecurity Regional Incident Preparedness and Response Playbook appeared first on HIPAA Journal.

FDA 82
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

EU and US Regulatory Challenges Facing AI Health Care Innovator Firms

Bill of Health

Beyond the health care sector-specific Medical Devices Regulation (EU) 2017/745 (MDR) and the In Vitro Diagnostic Medical Devices Regulation (EU) 2017/746 (IVDR), this mix of AI & Data related regulatory requirements stems from a series of generalized, cross-sectoral EU laws of the last 5 years.

FDA 282
article thumbnail

Five Reasons why the FDA got it Right with Digital Health

The Digital Health Corner

The FDA recently announced its Digital Health Innovation Action Plan. Digital health differs significantly from drugs and traditional medical devices around which the FDA has developed its structure and policies over decades. The FDA will have new digital health experts. This plan was both important and necessary.

FDA 87
article thumbnail

The Privatization of Cancer

Bill of Health

In fact, the majority of Americans do not hold strong trust in our health agencies like FDA and CDC. In 2017, 72% of U.S. There is an intuitive sense that products are not well regulated, leaving individuals to moderate their own cancer risk. I believe deregulation is one form of the “privatization of cancer.”

FDA 301
article thumbnail

Cognoa Appoints Former CMO, Dr. Sharief Taraman as CEO

HIT Consultant

– Dr. Taraman served as the company’s Chief Medical Officer since 2017, leading clinical evidence generation and regulatory milestones of Canvas Dx and those resulting in FDA Breakthrough Device Designation of Cognoa’s autism digital therapeutic.

FDA 95
article thumbnail

FDA Guidance Shows a Regulatory Path Forward for Interoperable Devices

Exeed Regulatory Compliance

A new FDA guidance offers helpful recommendations for design and premarket submission. According to a 2018 Deloitte Consulting report, the market for interconnected medical devices is expected to grow from $15 billion in 2017 to $52 billion by 2025. Medical device industry is changing fast!

FDA 52